logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. A cost effectiveness analysis of cyclosporine in rheumatoid arthritis.

    Article - En anglais

    Objective

    To perform a cost effectiveness analysis of cyclosporine (CyA) in the treatment of rheumatoid arthritis (RA).

    Methods

    Five randomized controlled parallel group clinical trials were selected for metaanalysis.

    A fixed effects model was used to calculate the treatment effects among the studies.

    An incremental economic analysis was performed from both a societal perspective and the perspective of Ontario Ministry of Health (MOH).

    A placebo comparison and 2 head to head comparisons were performed.

    The total treatment cost was calculated for a typical patient based on a modified intent to treat approach modelled over a one year period.

    Results

    CyA produced a 25% or greater improvement in tender joint count in 35% of the patients relative to 17% of patients receiving placebo.

    There was no significant difference in improvement between CyA and azathioprine (Aza) or D-penicillamine (D-Pen).

    From the perspective of the Ontario MOH, the annual incremental cost of achieving the same level of improvement between CyA and Aza was found to be $1,473, and between CyA and D-Pen, $1,618 ; the annual incremental cost effectiveness ratio per patient improved of adopting CyA over placebo was $11,547.

    From a societal perspective, the incremental cost of CyA was $2,886 and $3,731 between Aza and D-Pen, respectively.

    The annual incremental cost effectiveness ratio against placebo was $20,698.

    Conclusion

    Given budgetary constraints on provincial drug plans, guidelines ...

    Mots-clés Pascal : Polyarthrite rhumatoïde, Homme, Ciclosporine, Chimiothérapie, Traitement, Analyse coût efficacité, Economie santé, Chronique, Immunomodulateur, Antirhumatismal, Système ostéoarticulaire pathologie, Rhumatisme inflammatoire, Immunopathologie, Maladie autoimmune

    Mots-clés Pascal anglais : Rheumatoid arthritis, Human, Chemotherapy, Treatment, Cost efficiency analysis, Health economy, Chronic, Immunomodulator, Antirheumatic agent, Diseases of the osteoarticular system, Inflammatory joint disease, Immunopathology, Autoimmune disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0214775

    Code Inist : 002B02L. Création : 199608.